Novo Nordisk CEO Lars Fruergaard Jorgensen to Depart Amid Share Decline: Pharma and Biotech Daily Update

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Novo Nordisk CEO Lars Fruergaard Jorgensen is set to depart as the Danish pharma company's shares have been on a decline. During Jorgensen's eight-year tenure, the company saw significant growth in sales, profits, and share price, nearly tripling in value. However, since mid-2024, the shares have dropped by half in just one year. Jorgensen's departure comes as a surprise given the company's previous success under his leadership.